Refine Search

New Search

Advanced search

Results: 13

(searched for: ((title:Technology Audit and Production Reserves) OR (abstract:Technology Audit and Production Reserves)))
Page of 2
Articles per Page
by
Show export options
  Select all
Vladimir Simonenko, Artem Pavlychenko, Oleksii Cherniaiev
Technology audit and production reserves, Volume 5, pp 21-27; doi:10.15587/2312-8372.2018.145602

Abstract: The object of research is the environmental safety of the functioning of mining enterprises. One of the most problematic places there are significant differences in the mining and geological conditions and geometrical parameters of the quarries, the type and technical condition of the mining and transportation equipment used in mining enterprises, as well as the need to refine
reserves
in a reduced sanitary protection zone. Changes in the procedure for assessing the environmental impact of a planned activity by mining enterprises should include the development and implementation of additional
technological
solutions that will help reduce pollution in the adjacent territories. Therefore, there is a need to develop standardized approaches, the use of which will allow analyzing the
technological
processes of mining enterprises and be more dangerous from an environmental point of view, where significant amounts of pollutant emissions are generated.In the course of the study, three typical
technological
schemes for the development of deposits of rocky building materials, differing in
productivity
and emissions of pollutants to adjacent territories, have been analyzed. It has been established that the use of belt conveyors allows reducing the zone of influence of an enterprise on the ecological state of adjacent territories and minimizing the environmental risks of the functioning of mining enterprises.For the localization of emissions of pollutants in the mining enterprise, it is reasonable to place mobile and portative crushing and screening plants in a quarry directly in the faces or at work sites. This will reduce environmental pollution levels and increase the comfort of living in the mining regions.Thanks to the use of modern research methods, methods of cartographic modeling and scientific forecasting and the use of computer programs, optimal environmental-friendly field development
technologies
have been developed. Their use will reduce emissions of pollutants outside the sanitary protection zone and improve the environmental image of the mining enterprise. Such approaches will contribute to the successful passage of the environmental
audit
of mining enterprises, obtaining international environmental certificates and the development of new markets for
products
.
E.A. Lyaskovskaya, Sciprofile linkM.R. Kurbangaliev
Published: 26 June 2017
SHS Web of Conferences, Volume 35; doi:10.1051/shsconf/20173501129

Abstract: In the intensifying condition of economic situation and increasing competitiveness in domestic and foreign markets, the most important way to develop competitive ability of an industrial company is to reduce energy costs in the
production
process. Insufficient level of the efficiency of energy resources usage affects an industrial company’s performance indicators and its investment attractiveness. A promising way of solving this matter is to develop and implement a strategy of rational energy consumption, which is aimed at the realization of company’s potential to optimize the consumption of electric energy by using internal and external resources in order to minimize energy costs. The strategy of rational energy consumption defines how an industrial company acquires electric energy and uses it to sustain the
production
. While developing and implementing the strategy, one should use a systemic and complex way and consider the following: peculiarities of electric energy and power as
products
; the structure of electric energy market and the possibilities of its consumers; peculiarities of price-formation on electric energy market; technical and
technological
, organizational and administrative, social and economic parameters of a company, characteristic features of its resource potential and
production
processes; the results of company’s energy efficiency
audit
and energy problems; company’s
reserves
that can increase its energy efficiency. An integral strategy of energy consumption includes a strategy for energy preservation and efficiency and a strategy for energy costs management. Both strategies are interrelated and serve for one purpose, which is minimizing the energy costs. This division helps simplify the analysis, search for alternatives and realization of energy management on operative, tactical and strategic levels, considering the regional and industry-specific peculiarities of an industrial company, its financial performance and efficiency.
Akshay Deshpande, Kaustubh Karnataki, Kavya Darshana, Pranav Deshpande, Mitavachan H., Ganesh Shankar
2015 International Conference on Advanced Computing and Communications (ADCOM) pp 22-26; doi:10.1109/adcom.2015.11

The publisher has not yet granted permission to display this abstract.
Sciprofile linkDerek Johnson, April Covington
Volume 4A: Dynamics, Vibration, and Control; doi:10.1115/imece2014-38582

The publisher has not yet granted permission to display this abstract.
Technology audit and production reserves; doi:10.15587/2312-8372

S. V. Shaklein, M. V. Pisarenko
Journal of Mining Science, Volume 50, pp 527-532; doi:10.1134/s1062739114030144

The publisher has not yet granted permission to display this abstract.
Lidia Hrnčević, Katarina Simon, Zdenko Kristafor, Matija Malnar
SPE Deep Gas Conference and Exhibition; doi:10.2118/132153-ms

The publisher has not yet granted permission to display this abstract.
Sciprofile linkV. Jegatheesan, Sciprofile linkJong Leng Liow, L. Shu, S.H. Kim, C. Visvanathan
Published: 1 May 2009
Journal of Cleaner Production, Volume 17, pp 637-643; doi:10.1016/j.jclepro.2008.11.016

The publisher has not yet granted permission to display this abstract.
John Robert Etherington
SPE Annual Technical Conference and Exhibition; doi:10.2118/124938-ms

The publisher has not yet granted permission to display this abstract.
Published: 19 November 2007
by Wiley
Prescriber, Volume 18, pp 8-12; doi:10.1002/psb.156

Abstract: Glitazones: benefits outweigh the risksFollowing a review of the safety of rosiglitazone and pioglitazone, the European Medicines Agency (EMEA) has concluded that their benefits outweigh their risks in the approved indications. The review was prompted by reports of an increased risk of fractures in women and, in patients taking rosiglitazone, ischaemic heart disease. The EMEA concluded that prescribing information for rosiglitazone should now include a warning that, in patients with ischaemic heart disease, it should only be used after careful evaluation of each patient's individual risk, and the combination of rosiglitazone and insulin should only be used in exceptional cases and under close supervision.No change was considered necessary to the prescribing information for pioglitazone. Modern dressings no better?A systematic review has found only weak evidence that modern dressings are better than saline gauze or paraffin gauze for healing acute and chronic wounds (Arch Dermatol 2007;143: 1297‐304).The analysis, which included 99 studies, found that only hydrocolloids were demonstrably better than older dressings for healing chronic wounds, and alginates were superior to other modern dressings for debriding necrotic wounds. There was no evidence that modern dressings offered superior overall performance to the older alternatives.Hospital inflation twice primary care levelThe cost of drugs prescribed in secondary care but dispensed in the community increased by 6.4 per cent in 2006 ‐ twice the rate of inflation in primary care ‐ according to the latest statistics on hospital prescribing in England. The increase follows a reduction in costs in 2005 after the introduction of the new PPRS scheme. Data from The Information Centre (www.ic.nhs.uk) show that hospital medicines make up about 24 per cent of the NHS drugs budget. Secondary care has a consistently better record than primary care in prescribing lower‐cost alternatives within therapeutic categories, eg simvastatin and pravastatin among the statins, omeprazole and lansoprazole among PPIs, and ACE inhibitors among drugs acting on the renin angiotensin system. The most expensive drug prescribed by hospital specialists and dispensed in the community is interferon beta.MHRA limits the use of fibratesThe Medicines and Healthcare
products
Regulatory Agency (MHRA) has advised that fibrates should now be
reserved
for the treatment of isolated severe hypertriglyceridaemia. They should be considered for hypercholesterolaemia only when a statin or other treatment is contraindicated or not tolerated.In the latest Drug Safety Update, the MHRA says there is insufficient evidence of long‐term benefits from fibrates, and first‐line use is no longer justified because the evidence for the benefits of statins is robust. The MHRA also warns that some breastfeeding infants have increased susceptibility to the adverse effects of codeine taken by their mother, and that St John's wort may affect the hepatic metabolism of any anticonvulsant. Annual zoledronic acid infusion cuts mortality after hip fractureOnce‐yearly infusion of zoledronic acid (Aclasta) after hip fracture reduces deaths over a two‐year period by 28 per cent compared with placebo, US investigators say (N Engl J Med 2007;357:1799‐809).The HORIZON Recurrent Fracture Trial randomised 2127 men and women (mean age 75) within 90 days of surgery for hip fracture to zoledronic acid 5mg yearly or placebo. Mortality over 1.9 years of follow‐up was 9.6 per cent with zoledronic acid and 13.3 per cent with placebo.Zoledronic acid also significantly reduced the rate of any new clinical fractures (by 35 per cent) and new clinical vertebral fractures(by 45 per cent),but the lower rate of hip fracture (2.0 vs 3.5 per cent with placebo) was not statistically significant.Rivastigmine patch for mild to moderate ADRivastigmine (Exelon) is now available as a transdermal patch for the treatment of mild to moderate Alzheimer's disease. Applied once daily, the patch delivers 9.5mg per 24 hours and, says manufacturer Novartis, is associated with a lower incidence of nausea and vomiting than a comparable oral dose. The patch is available in two strengths: 4.6mg per 24hr is equivalent to oral doses of 3 or 6mg per day, and the 9.5mg per 24hr patch is equivalent to 9 or 12mg per day orally. The recommended dose of the patch is 9.5mg per day; both strengths cost £83.84 for 30 patches. Women more aspirin resistant than men?The cardioprotective effect of low‐dose aspirin may be lower in women than men, say Canadian investigators (BMC Medicine 2007;5:29 doi: 10.1186/1741‐70155‐29).Their meta‐analysis of 23 randomised trials involving a total of 113 494 participants found that aspirin significantly reduced the risk of nonfatal but not fatal myocardial infarction (MI). About one‐quarter of the variation in its effects on nonfatal MI was accounted for by the sex mix of the trial population. Separating the results by sex showed the reduction in risk with aspirin use was statistically significant in men (relative risk, RR, 0.62) but not in women (RR 0.87).Look after physical health of mentally illGPs and other primary care workers should take more responsibility for the physical health of their mentally ill patients, say advocacy groups.Mind and Body: Preventing and Improving Physical Health Problems in Patients With Schizophrenia points out that the mental health needs of patients with schizophrenia are met in secondary care, but their physical health needs should be met in primary care. In particular, the metabolic effects of antipsychotics may lead to obesity, diabetes and cardiovascular disease, and weight gain in particular is a frequent reason for nonadherence to treatment.The Mind and Body Manifesto was developed by SANE, The Mental Health Nurses Association, The National Obesity Forum and The Disability Rights Commission and sponsored by Bristol‐Myers Squibb Pharmaceuticals Limited and Otsuka Pharmaceuticals (UK) Ltd. Copies are available from [email protected] ogilvyhealthworld.com.Health eCard costsSome costs quoted in our article on the Health eCard (The Health eCard: the way ahead for medical records?,5 October issue, pages 28‐9) have been revised: the card and initial download will cost patients £39.50, and GPs will be entitled to charge patients £10 per annum for subsequent downloads.NICE appraisals of cytokine inhibitors in RANICE has endorsed the use of the anti‐TNF agents adalimumab (Humira), etanercept (Enbrel) and infliximab (Remicade), normally in conjunction with methotrexate, for the treatment of active RA when methotrexate and another DMARD have failed (also see New from NICE below).NICE has provisionally concluded, subject to consultation, that abatacept (Orencia) should not be recommended for the treatment of RA.Boots and BMJ launch health advice sitewww.askbootshealth.com is a new website providing information about health and medicines for the public produced by Boots using information provided by the BMJ Publishing Group. The website covers many of the topics already available from NHSDirect, with perhaps more information about available treatments.Diabetes care shows small improvementThe third National Diabetes
Audit
in England and Wales has found that more people with diabetes were achieving the targets set by NICE for cholesterol levels, glycaemic control and blood pressure in 2005/06 ‐ but younger patients were doing less well. Overall, the HbA1C target of ≤7.5 per cent was achieved in 60 per cent of people with diabetes compared with 58 per cent in 2004/05. However, HbA1C was >9.5 per cent in 30 per cent of children and young people, of whom 9 per cent experienced at least one episode of ketoacidosis.More topics for NICENew topics referred to NICE include clinical guidelines on ovarian cancer, coeliac disease and stable angina, public health guidance on preventing cardiovascular disease, and
technology
appraisals on insulin detemir (Levemir) for type 1 diabetes, several treatments for cancer and hepatic and haematological disorders, and biological therapies for juvenile arthritis.New from NICENICE appraisal on anti‐TNFs for RASince NICE published its first appraisal of agents acting against tumour necrosis factor‐alpha (anti‐TNFs) for the treatment of RA in 2002, the
product
licences for etanercept (Enbrel) and infliximab (Remicade) have changed and a new agent, adalimumab (Humira), has been introduced.The anti‐TNFs act in different ways. Infliximab is a chimeric monoclonal antibody that binds to TNF‐alpha, neutralising its activity. Etanercept, a recombinant human TNF‐alpha receptor fusion protein, and adalimumab, a human‐sequence antibody, both bind to TNF‐alpha and block its interaction with cell surface receptors. Adalimumab also modulates some biological responses induced or regulated by TNF‐alpha.These agents are recommended for adults with severe active RA (defined as a disease activity score ‐ DAS28 ‐ greater than 5.1) who have already tried two disease‐modifying drugs, including methotrexate (if not contraindicated). Prior treatment should have been of at least six months' duration, including two months at the standard dose (unless limited by toxicity).Anti‐TNFs should normally be prescribed with methotrexate; when this is not appropriate, etanercept and adalimumab may be prescribed as monotherapy. Treatment with an anti‐TNF should be continued beyond six months only if there is an adequate response (defined as an improvement in DAS28 of at least 1.2). Data from the British Rheumatology Society Biologics register show that, after six months, 67 per cent of patients met NICE criteria for an adequate response; this declined to 55 per cent at 18 months.The basic annual cost of treatment is £9295 for adalimumab 40mg on alternate weeks or etanercept 25mg twice weekly; infliximab costs £3777 for a loading dose, then £7553‐£8812 depending on dose. Assuming no progression of disability, the incremental costs per QALY (
Page of 2
Articles per Page
by
Show export options
  Select all